3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Interventions
pembrolizumab
75
Carboplatin
61
Cyclophosphamide
58
Nivolumab
50
Paclitaxel
47
Gemcitabine
44
Cisplatin
43
Dexamethasone
41
Radiotherapy
35
Rituximab
32
Capecitabine
31
Docetaxel
29
Bevacizumab
29
fludarabine
27
atezolizumab
26
Cytarabine
26
avelumab
24
Trastuzumab
23
Oxaliplatin
23
Lenalidomide
23
Cetuximab
23
venetoclax
22
Fluorouracil
22
Azacitidine
22
Temozolomide
21
Ipilimumab
21
130-nm albumin-bound paclitaxel
21
fludarabine phosphate
20
Filgrastim
20
Bortezomib
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Terminated
×
forodesine
×
Clear all
NCT00742495
2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2
Terminated
2 enrolled